Francis W. Chen has more than twenty years of management experience in the healthcare industry and more than fifteen years as an entrepreneur and investor in high-tech and bio-tech start-ups. He is the founder and Chairman of SinoAmerican Partners Limited that provides advisory services for transactions in life sciences, information technologies and financial services. Francis is formerly Vice Chairman of WI Harper Group, a venture capital firm focusing on early-stage investments in Silicon Valley, China and Taiwan. WI Harper Group is one of the pioneers in cross-border technology investments between US and Greater China. Francis was also active in the formation of the first Sinovation Ventures fund (formerly known as Innovation Works) founded by Dr. Kai-Fu Lee and WI Harper, with notable unicorns including Megvii, Meitu, and Zhihu. Francis has served as a director of several technology-based companies and has been an independent board member of Stealth BioTherapeutics (Nasdaq: MITO) since its founding by Morningside Group in 2006. He currently advises Arrive Bio, Donisi Health, Innodem Neurosciences, Nanomedic Tehnologies and Sanolla. He began his career in operating management positions with Becton Dickinson, Baxter Healthcare and Hygeia Sciences where he was one of the senior executives that took the Company public on Nasdaq and ultimately its acquisition by Tambrands. Francis was also a co-founder and Chief Operating Officer of Scotgen Biopharmaceuticals – one of the first generation biotech companies in the commercialization of genetically-engineered antibodies for therapeutic applications.

He served as a trustee of several non-profit organizations: San Francisco Opera Association, Groton School and Sanford Burnham Prebys Medical Discovery Institute. Francis holds a Ph.D. in immunology from Harvard University and an M.S. and a B.S. in chemistry from Tufts University